Cutaneous B-cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy

被引:20
作者
Clarke, LE
Bayerl, MG
Ehmann, WC
Helm, KF
机构
[1] Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Pathol, Hershey, PA 17033 USA
[2] Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Med, Hershey, PA 17033 USA
[3] Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Dermatol, Hershey, PA 17033 USA
关键词
D O I
10.1034/j.1600-0560.2003.00078.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Antibodies to the B-cell-specific antigen CD20 are widely used for immunohistochemical identification of B-cell lymphomas, approximately 95% of which are strongly CD20-positive. Methods: We report a 51-year-old male with a CD20-positive systemic B-cell lymphoma who developed a CD20-negative relapse with secondary cutaneous involvement after therapy with the anti-CD20 monoclonal antibody rituximab (Rituxan). Results: Biopsy of a skin nodule demonstrated an atypical lymphocytic infiltrate that was negative for CD20, CD3, lysozyme, and myeloperoxidase, but strongly positive for CD45rb (LCA) and the B-cell marker CD79a. Conclusions: We conclude that loss of CD20 expression in cutaneous B-cell lymphoma (both primary and secondary) is important to recognize, that immunohistochemistry for CD79a, another widely expressed B-cell marker, is useful in the identification of CD20-negative B cells in such cases, and that loss of CD20 expression may become more common, as use of rituximab is expected to increase.
引用
收藏
页码:459 / 462
页数:4
相关论文
共 10 条
[1]   Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma [J].
Berinstein, NL ;
Grillo-Lopez, AJ ;
White, CA ;
Bence-Bruckler, I ;
Maloney, D ;
Czuczman, M ;
Green, D ;
Rosenberg, J ;
McLaughlin, P ;
Shen, D .
ANNALS OF ONCOLOGY, 1998, 9 (09) :995-1001
[2]   CD79: A review [J].
Chu, PG ;
Arber, DA .
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2001, 9 (02) :97-106
[3]  
Davis TA, 1999, CLIN CANCER RES, V5, P611
[4]   Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis [J].
Foran, JM ;
Norton, AJ ;
Micallef, INM ;
Taussig, DC ;
Amess, JAL ;
Rohatiner, AZS ;
Lister, TA .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 114 (04) :881-883
[5]   Rituximab:: Ongoing and future clinical development [J].
Grillo-López, AJ ;
Hedrick, E ;
Rashford, M ;
Benyunes, M .
SEMINARS IN ONCOLOGY, 2002, 29 (01) :105-112
[6]   Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review [J].
Kennedy, GA ;
Tey, SK ;
Cobcroft, R ;
Marlton, P ;
Cull, G ;
Grimmett, K ;
Thomson, D ;
Gill, D .
BRITISH JOURNAL OF HAEMATOLOGY, 2002, 119 (02) :412-416
[7]  
Kinoshita T, 1998, J CLIN ONCOL, V16, P3916
[8]   CD79A - A NOVEL MARKER FOR B-CELL NEOPLASMS IN ROUTINELY PROCESSED TISSUE SAMPLES [J].
MASON, DY ;
CORDELL, JL ;
BROWN, MH ;
BORST, J ;
JONES, M ;
PULFORD, K ;
JAFFE, E ;
RALFKIAER, E ;
DALLENBACH, F ;
STEIN, H ;
PILERI, S ;
GATTER, KC .
BLOOD, 1995, 86 (04) :1453-1459
[9]   CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy [J].
Massengale, WT ;
McBurney, E ;
Gurtler, J .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2002, 46 (03) :441-443
[10]  
Salama S, 2000, Am J Clin Pathol, V114 Suppl, pS104